

# Hindustan Unilever

Estimate changes	↔
TP change	↔
Rating change	↔

Bloomberg	HUVR IN
Equity Shares (m)	2350
M.Cap.(INRb)/(USDb)	6112.7 / 69.6
52-Week Range (INR)	2780 / 2136
1, 6, 12 Rel. Per (%)	0/1/-8
12M Avg Val (INR M)	4394

Financials & Valuations (INR b)			
Y/E March	2026E	2027E	2028E
Sales	672.8	729.8	788.2
Sales Gr. (%)	6.6	8.5	8.0
EBITDA	154.4	172.8	185.8
EBITDA mrg. (%)	22.9	23.7	23.6
Adj. PAT	107.7	122.5	132.6
Adj. EPS (INR)	45.8	52.1	56.4
EPS Gr. (%)	3.3	13.8	8.2
BV/Sh.(INR)	214.0	221.2	229.6
Ratios			
RoE (%)	21.6	24.0	25.0
ROCE (%)	29.8	32.7	34.1
Payout (%)	91.7	86.3	85.0
Valuations			
P/E (x)	56.8	49.9	46.1
P/BV (x)	12.1	11.8	11.3
EV/EBITDA (x)	39.4	35.1	32.5
Div. Yield (%)	1.6	1.7	1.8

Shareholding Pattern (%)			
As On	Jun-25	Mar-25	Jun-24
Promoter	61.9	61.9	61.9
DII	16.1	15.6	14.2
FII	10.2	10.6	11.9
Others	11.9	11.9	12.1

FII includes depository receipts

**CMP: INR2,602**      **TP: INR3,050 (+17%)**      **Buy**

## Macro drivers constructive; expectations rising for 2HFY26

- Hindustan Unilever's (HUVR) 2QFY26 consolidated revenue rose 2% at INR162.5b (in line), with flat underlying volume growth (est. 2.5% and 4% in 1QFY26). Demand trends remained stable; however, the GST transition and prolonged monsoon weighed on performance during the quarter. The GST transition and trade pipeline adjustments impacted volume growth by ~2%. Nonetheless, management expects 2HFY26 to be better than 1HFY26.
- Home Care delivered mid-single-digit volume growth, while revenue declined 1% YoY, given price cuts taken in 1QFY26. Fabric Wash volumes grew in mid-single digits, driven by strong double-digit volume growth in liquids. EBIT margin contracted 30bp YoY to 19.1%.
- The Beauty & Wellbeing segment witnessed flattish volume growth, with revenue increasing 9%, driven by Skin Care and Health & Wellbeing. Channels of the Future maintained its competitive, double-digit growth trajectory. Skin Care and Colour Cosmetics grew in high single digits. EBIT margin contracted 440bp to 28.4% due to higher investments in brands and innovations.
- Personal Care posted flat YoY revenue growth, impacted by the GST rate transition during the quarter. Volumes declined to high single digits, supported by calibrated price hikes amid commodity inflation. Oral Care witnessed a marginal decline. EBIT margin expanded 340bp YoY to 20.3%, with EBIT rising 21%.
- Food & Refreshment (F&R) revenue grew 2%, with a low single-digit UVG. Beverages grew in double digits. Lifestyle Nutrition showed early green shoots with sustained UVG. However, sales were impacted by pricing actions taken in previous quarters to refine the pack-price architecture. Packaged Foods delivered a subdued performance amid the GST transition. However, EBIT declined 9% YoY.
- Under the new leadership, HUVR continues to remain focused on driving volume-led earnings growth, even if it comes at the expense of near-term margins. With various strategies underway, optimism is building for stronger operational performance in the coming quarters. We believe the new leadership is well-positioned to capitalize on its volume growth aspirations amid supportive macro drivers. We reiterate our BUY rating on the stock with a TP of INR3,050 (55x on Sep'27E EPS).

## In-line performance; volume growth flat YoY

- Net sales grew 2.1% YoY to INR160.6b (est. INR160.6b), while UVG remained flat YoY (est. 2.5% and 4% in 1QFY26). Total revenue rose 2% YoY to INR162.5b (est. INR162.6b). **Home Care** revenue declined 1% YoY (with UVG up mid-single digit), **Beauty and Wellbeing** rose 9.1% YoY (UVG flat), **Personal Care** remained flat YoY (UVG up high-single digit decline), and **Food & Refreshment** sales grew 2% YoY (UVG up low-single digit).

- Gross margins for the quarter contracted 20bp YoY to 51.4% (est. 50.7%). Employee expenses declined 9% YoY, while other expenses rose 5% YoY and ad spends rose 11% YoY. EBITDA margin contracted 80bp YoY to 23%. (est. 22.4%). The company expects EBITDA margin to remain at current levels in the near term.
- EBITDA declined 1% YoY to INR37.4b (est. INR36.5b), PBT declined 5% YoY to INR34b (est. INR34.2b), and PAT (bei) declined 4% YoY to INR25b (est. INR25.5b). Reported PAT rose 4.1% YoY to INR26.9b.
- An exceptional item of INR1,840m relates to the one-off positive impact from the resolution of prior-year tax matters between the UK and Indian tax authorities, along with restructuring expenses and acquisition- and disposal-related costs.
- In 1HFY26, net sales, EBITDA, and APAT grew 4%, -1%, and 5%, respectively.
- HUVR has declared an interim dividend of INR19 per equity share, each with a face value of INR1.

### Management conference call highlights

- HUL's ~40% portfolio has transitioned to the 5% GST bracket, and the company has undertaken pricing and grammage revisions across more than 1,200 SKUs to reflect the changes.
- Management expects the combined impact of GST cuts, easing inflation, and a more accommodative monetary policy to drive a gradual recovery in consumption, particularly in rural markets.
- Volume impact of ~2% during the quarter was attributed to the GST transition and trade pipeline adjustments.
- E-commerce contributes 8% to total sales (12% in urban markets), while general trade forms 70% and modern trade about 20%, with all channels recording growth.
- The near-term EBITDA margin guidance remains in the 22-23% range, with 50-60bp expansion expected following the demerger, as the low-margin Ice Cream business will be excluded.

### Valuation and view

- We largely maintain our estimates for FY26-FY28.
- The company plans to focus aggressively on volume acceleration, alongside new launches and the reactivation of its value proposition, which is expected to drive further growth from 2HFY26 onwards.
- We expect supportive macroeconomic factors to act as a catalyst for boosting consumption sentiment. As a market leader in most staple categories, coupled with its strategic initiatives, HUVR is well-positioned to benefit the most.
- We model an 8%/8%/9% revenue, EBITDA, and APAT CAGR over FY25-28E. With various strategies underway, optimism is building for stronger operational performance in the coming quarters. We believe the new leadership is well-positioned to capitalize on its volume growth aspirations amid supportive macro drivers. We reiterate our BUY rating on the stock with a TP of INR3,050 (55x on Sep'27E EPS).

Y/E March	(INR b)											
	FY25					FY26E				Var.		
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE				
<b>Domestic volume growth (%)</b>	<b>4.0</b>	<b>3.0</b>	<b>0.0</b>	<b>2.0</b>	<b>4.0</b>	<b>0.0</b>	<b>7.5</b>	<b>8.5</b>	<b>2.0</b>	<b>5.0</b>	<b>2.5</b>	
<b>Net sales (INR b)</b>	<b>155.2</b>	<b>157.3</b>	<b>155.9</b>	<b>154.5</b>	<b>163.2</b>	<b>160.6</b>	<b>170.2</b>	<b>170.5</b>	<b>622.9</b>	<b>664.4</b>	<b>160.6</b>	0.0%
YoY change (%)	1.7	2.4	1.9	2.7	5.2	2.1	9.2	10.4	2.2	6.7	2.1	
Other operating income	1.8	2.0	2.3	2.2	1.9	1.9	2.3	2.3	8.3	8.4	2.0	
<b>Total revenue</b>	<b>157.1</b>	<b>159.3</b>	<b>158.2</b>	<b>156.7</b>	<b>165.1</b>	<b>162.5</b>	<b>172.5</b>	<b>172.6</b>	<b>631.2</b>	<b>672.8</b>	<b>162.6</b>	-0.1%
YoY change (%)	1.4	1.9	1.6	3.0	5.1	2.0	9.0	10.2	2.0	6.6	2.1	
COGS	75.5	77.1	77.0	76.2	82.4	78.9	84.2	84.2	306	330	80.2	
<b>Gross Profit</b>	<b>81.6</b>	<b>82.2</b>	<b>81.2</b>	<b>80.5</b>	<b>82.7</b>	<b>83.6</b>	<b>88.3</b>	<b>88.5</b>	<b>325.4</b>	<b>343.1</b>	<b>82.5</b>	
Margin %	52.0	51.6	51.3	51.4	50.1	51.4	51.2	51.3	51.6	51.0	50.7	
<b>EBITDA</b>	<b>37.4</b>	<b>37.9</b>	<b>37.0</b>	<b>36.2</b>	<b>37.2</b>	<b>37.4</b>	<b>39.9</b>	<b>39.9</b>	<b>148.5</b>	<b>154.4</b>	<b>36.5</b>	2.5%
YoY change (%)	2.2	-0.1	0.8	2.4	-0.7	-1.4	7.9	10.3	1.3	3.9	-3.8	
Margins (%)	23.8	23.8	23.4	23.1	22.5	23.0	23.1	23.1	23.5	22.9	22.4	
Depreciation	3.3	3.4	3.4	3.5	3.6	3.6	3.6	3.6	13.6	14.4	3.6	
Interest	0.9	1.1	1.1	0.8	1.3	1.3	1.1	0.4	4.0	4.0	1.0	
Other income	2.6	2.2	2.3	3.1	2.0	1.5	2.6	3.3	10.2	9.3	2.3	
<b>PBT</b>	<b>35.8</b>	<b>35.6</b>	<b>34.7</b>	<b>35.0</b>	<b>34.3</b>	<b>34.0</b>	<b>37.7</b>	<b>39.2</b>	<b>141.2</b>	<b>145.2</b>	<b>34.2</b>	-0.6%
Tax	9.2	9.5	9.9	8.9	5.4	8.8	9.4	10.1	37.4	33.7	8.6	
Rate (%)	25.6	26.6	28.6	25.3	15.6	25.8	25.0	25.9	26.5	23.2	25.2	
<b>PAT bei</b>	<b>26.5</b>	<b>26.0</b>	<b>26.0</b>	<b>25.7</b>	<b>25.3</b>	<b>25.0</b>	<b>28.3</b>	<b>29.1</b>	<b>104.2</b>	<b>107.7</b>	<b>25.6</b>	-2.2%
YoY change (%)	2.5	-2.1	2.9	2.6	-4.5	-4.0	8.6	13.5	1.4	3.3	-1.8	
<b>Reported Profit</b>	<b>26.1</b>	<b>25.9</b>	<b>29.8</b>	<b>24.6</b>	<b>27.6</b>	<b>27.0</b>	<b>28.1</b>	<b>28.7</b>	<b>106.5</b>	<b>111.3</b>	<b>25.6</b>	

E: MOSL Estimates

#### Exhibit 1: Consolidated segmental performance

Segment Revenue (INR b)	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25	4QFY25	1QFY26	2QFY26
Home Care	53.1	54.4	57.1	56.7	57.3	57.4	58.2	57.8	56.6
Beauty & Personal Care	58.7	57.8	51.3	56.7	58.3	58.0	53.9	61.7	61.6
-Beauty and wellbeing	33.4	34.7	30.6	32.8	34.2	35.6	32.7	36.3	37.3
-Personal care	25.4	23.2	20.6	23.9	24.1	22.4	21.3	25.4	24.3
Foods & Refreshments	38.5	37.3	39.1	38.5	38.0	37.5	39.0	40.2	38.7
Others	5.9	6.1	4.7	5.2	5.6	5.4	5.7	5.5	5.5
<b>Net Segment Revenue</b>	<b>156.2</b>	<b>155.7</b>	<b>152.1</b>	<b>157.1</b>	<b>159.3</b>	<b>158.2</b>	<b>156.7</b>	<b>165.1</b>	<b>162.4</b>
<b>Growth YoY (%)</b>									
Home Care	3.2	(1.3)	1.3	4.6	8.0	5.4	1.9	1.8	(1.2)
Beauty & Personal Care	5.0	0.3	(2.5)	(0.0)	(0.7)	0.3	5.2	8.9	5.6
-Beauty and wellbeing	-	-	-	3.5	2.5	2.6	6.6	10.7	9.1
-Personal care	-	-	-	(4.5)	(4.9)	(3.1)	3.1	6.5	0.6
Foods & Refreshments	2.6	0.9	3.1	1.4	(1.2)	0.3	(0.4)	4.3	1.7
Others	(9.4)	(1.8)	(11.6)	(15.2)	(5.2)	(12.0)	21.9	6.4	(1.6)
<b>Net Segment Revenue</b>	<b>3.2</b>	<b>(0.2)</b>	<b>(0.0)</b>	<b>1.4</b>	<b>1.9</b>	<b>1.6</b>	<b>3.0</b>	<b>5.1</b>	<b>2.0</b>
<b>Salience (%)</b>									
Home Care	34.0	35.0	37.5	36.1	36.0	36.3	37.1	35.0	34.9
Beauty & Personal Care	37.6	37.1	33.7	36.1	36.6	36.7	34.4	37.4	37.9
-Beauty and wellbeing	21.4	22.3	20.1	20.9	21.5	22.5	20.8	22.0	23.0
-Personal care	16.2	14.9	13.6	15.2	15.1	14.2	13.6	15.4	14.9
Foods & Refreshments	24.6	24.0	25.7	24.5	23.9	23.7	24.9	24.3	23.8
Others	3.8	3.9	3.1	3.3	3.5	3.4	3.6	3.3	3.4
<b>Total Segment Revenue</b>	<b>100.0</b>								
<b>Segment Results (EBIT) - (INR b)</b>									
Home Care	10.1	9.9	11.1	11.4	11.1	10.9	10.9	11.3	10.8
Beauty & Personal Care	15.8	14.7	12.9	14.3	15.3	14.2	14.4	14.7	15.5
-Beauty and wellbeing	11.2	11.0	9.1	10.0	11.2	10.2	10.5	10.0	10.6
-Personal care	4.6	3.7	3.8	4.3	4.1	4.0	4.0	4.8	4.9
Foods & Refreshments	7.2	7.1	7.4	7.4	6.9	7.6	6.3	6.5	6.3
Others	1.8	1.9	0.7	1.2	1.2	0.9	1.1	1.0	1.1
<b>Total Segment Results</b>	<b>35.0</b>	<b>33.5</b>	<b>32.2</b>	<b>34.2</b>	<b>34.6</b>	<b>33.5</b>	<b>32.7</b>	<b>33.6</b>	<b>33.7</b>
<b>PBT</b>	<b>35.9</b>	<b>34.5</b>	<b>34.2</b>	<b>35.3</b>	<b>35.4</b>	<b>39.8</b>	<b>33.6</b>	<b>33.0</b>	<b>35.7</b>

Segment Revenue (INR b)	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25	4QFY25	1QFY26	2QFY26
<b>Growth YoY (%)</b>									
Home Care	14.6	(9.3)	3.6	12.1	9.9	9.8	(1.6)	(0.6)	(2.8)
Beauty & Personal Care	12.4	1.2	(5.4)	(3.1)	(3.3)	(3.1)	11.9	3.4	1.5
-Beauty and wellbeing	-	-	-	(2.2)	0.4	(7.1)	14.7	(0.2)	(5.5)
-Personal care	-	-	-	(5.3)	(12.3)	8.7	5.0	11.8	20.9
Foods & Refreshments	(3.2)	7.6	8.8	8.1	(4.2)	6.2	(15.2)	(11.4)	(8.8)
Others	7.6	(6.5)	(55.7)	(45.1)	(34.2)	(50.0)	45.9	(12.8)	(12.4)
<b>Total Segment Results</b>	<b>9.1</b>	<b>(1.4)</b>	<b>(2.1)</b>	<b>1.1</b>	<b>(1.3)</b>	<b>0.0</b>	<b>1.8</b>	<b>(1.7)</b>	<b>(2.4)</b>
<b>Salience (%)</b>									
Home Care	29.0	29.5	34.6	33.3	32.2	32.4	33.4	33.6	32.1
Beauty & Personal Care	45.2	43.7	40.2	41.8	44.3	42.3	44.1	43.9	46.1
-Beauty and wellbeing	31.9	32.7	28.4	29.3	32.5	30.4	32.0	29.8	31.5
-Personal care	13.3	11.0	11.8	12.4	11.8	12.0	12.2	14.1	14.6
Foods & Refreshments	20.6	21.2	23.0	21.6	20.0	22.5	19.2	19.4	18.7
Others	5.3	5.6	2.3	3.4	3.5	2.8	3.3	3.0	3.1
<b>Total Segment Results</b>	<b>100.0</b>								
<b>Segmental EBIT margin (%)</b>									
Home Care	19.1	18.2	19.5	20.0	19.4	18.9	18.8	19.5	19.1
Beauty & Personal Care	26.9	25.3	25.2	25.2	26.2	24.5	26.8	23.9	25.2
-Beauty and wellbeing	33.5	31.6	29.8	30.5	32.8	28.6	32.0	27.5	28.4
-Personal care	18.3	15.9	18.4	17.8	16.9	17.9	18.7	18.7	20.3
Foods & Refreshments	18.7	19.0	18.9	19.1	18.1	20.2	16.1	16.2	16.3
Others	31.1	30.9	15.9	22.6	21.6	17.6	19.0	18.5	19.2
<b>Total</b>	<b>22.4</b>	<b>21.5</b>	<b>21.1</b>	<b>21.7</b>	<b>21.7</b>	<b>21.2</b>	<b>20.9</b>	<b>20.3</b>	<b>20.8</b>
<b>EBIT margin change YoY (bps)</b>									
Home Care	189	(162)	44	134	33	76	(66)	(48)	(32)
Beauty & Personal Care	179	22	(78)	(81)	(70)	(87)	160	(128)	(101)
-Beauty and wellbeing	-	3,161	-	(176)	(68)	(298)	225	(300)	(440)
-Personal care	-	-	-	(16)	(142)	194	35	89	341
Foods & Refreshments	(112)	118	100	118	(55)	111	(281)	(288)	(189)
Others	491	(155)	(1,581)	(1,229)	(953)	(1,335)	313	(409)	(237)
<b>Total</b>	<b>123</b>	<b>(27)</b>	<b>(44)</b>	<b>(6)</b>	<b>(71)</b>	<b>(34)</b>	<b>(26)</b>	<b>(141)</b>	<b>(94)</b>

Source: Company, MOFSL



## Highlights from the management commentary

### Operational environment

- Management stated that the recent GST rate cuts are a positive structural reform that will help boost consumption, improve disposable income, and strengthen overall consumer sentiment.
- Around 40% of HUL's portfolio has transitioned to the 5% GST bracket, and the company has undertaken pricing and grammage revisions across more than 1,200 SKUs to reflect the changes.
- The company extended support to trade partners during the transition period to ensure price pass-through and smooth implementation across the network.
- Temporary disruptions were observed at distributor and retailer levels due to the GST rate revision, but management expects normal trading conditions to resume from early November.
- Management expects the combined impact of GST cuts, easing inflation, and a more accommodative monetary policy to drive a gradual recovery in consumption, particularly in rural markets.
- Volume impact of ~2% during the quarter was attributed to the GST transition and trade pipeline adjustments.
- Price elasticity varies by category, with higher elasticity seen in skin cleansing and tea, while home care continues to remain relatively resilient.

- E-commerce now contributes about 8% of overall sales and around 12% of urban sales, reflecting its growing importance in the channel mix.
- The company remains in the investment phase for e-commerce, following a 'design-for-channel' strategy to develop packs suited for e-commerce and quick commerce platforms while managing channel profitability.
- Over 50% of HUL's marketing investments are now allocated to digital media, supported by ROI-focused execution and data-driven insights from its in-house analytics platform, Sangam.
- The company continues to drive premiumization across categories, particularly in laundry and personal wash, with consumers gradually upgrading from powders to liquids and from soaps to body washes.
- Management noted that body wash penetration remains low at about 2%, compared to 7-8% for laundry liquids, indicating a significant opportunity for future growth.
- HUL remains focused on driving **volume-led competitive growth** through four strategic pillars: 1) sharper consumer segmentation, 2) modernizing core and premium brands, 3) strengthening marketing capabilities, and 4) reshaping the portfolio around high-growth demand spaces.
- HUL continues to focus on developing underpenetrated categories and shaping consumer habits to expand its market leadership across 85% of its portfolio.
- Management reiterated its medium-term focus on achieving volume-led growth and building long-term category development rather than short-term margin maximization.
- The company believes FY27 will serve as a more accurate benchmark for assessing the impact of its ongoing strategic initiatives and structural changes.
- The GST rate cuts have benefited about 40% of the portfolio, including Skin Cleansing, Packaged Foods, and Hair Care, though short-term disruption impacted these categories.
- The trade pipeline spans 4-6 weeks, with normalization occurring faster in modern trade and e-commerce, while general trade takes longer due to its 9m outlet reach.
- Home Care grew volumes in mid-single digits, demonstrating resilience, while Tea and Skin Care delivered high single-digit growth, both led by volume.
- The Horlicks portfolio showed early signs of recovery, with green shoots visible in the nutrition category.
- The company remains focused on volume-led revenue growth and expects consumption to improve with higher net disposable income and better consumer sentiment.
- Urban markets account for two-thirds of consumption, while rural represents two-thirds of livelihoods; demand in both segments remains stable with a positive outlook.
- The company has loaded its winter portfolio into trade ahead of the season and expects a good winter to drive strong offtake.
- HUL continues to invest in brand innovation, with early success from the re-launch of Glow & Lovely, expansion of the personal care portfolio, and competitiveness improvement in Lifebuoy despite GST-led disruption.
- Skin Cleansing and Tea are price-elastic categories benefiting from commodity deflation, while Home Care remains largely price inelastic.

- HUL continues to adapt its pack-price architecture, improving grammage and introducing revised price points, with most new packs expected to be in trade by early November.
- E-commerce contributes 8% of total sales (12% in urban markets), while general trade forms 70% and modern trade about 20%, with all channels recording growth.
- Management highlighted India's 400m Gen-Z consumers as a key focus group, driving initiatives to enhance packaging, product propositions, and bold marketing for stronger youth engagement.

#### Costs and margins

- Near-term EBITDA margin guidance remains in the 22-23% range, with 50-60bp improvement expected following the demerger, as the low-margin Ice Cream business is excluded.
- Ice Cream contributes around 3% of overall sales and operates at low single-digit margins. Post the demerger (expected in 3QFY26), margins will reflect excluding the Ice Cream business.
- Management guided that the GST rate change will have no material impact on EBITDA margins in the medium term.
- The company reiterated that commodities remained divergent — palm oil and SMP were inflationary, while tea and crude oil prices trended lower during the quarter.
- Employee and other expenses together accounted for 18-18.5% of sales, fluctuating slightly through the quarter.

#### Segmental highlights

##### Home Care

- Home Care delivered a sustained competitive, volume-led performance on a strong base.
- The segment reported mid-single digit UVG, which was offset by price reductions taken in previous quarters, resulting in a flat USG.
- Fabric Wash recorded mid-single digit volume growth, driven by strong double-digit growth in liquids, supported by successful innovations and competitive pricing actions.
- Household Care achieved double-digit UVG, led by robust growth in dishwash liquids.
- During the quarter, the company launched Comfort Perfume Deluxe, a premium fabric conditioner inspired by award-winning fragrances, featuring a perfume-first formulation that delivers a sophisticated fragrance experience for clothes.

##### Beauty & Wellbeing

- Beauty & Wellbeing delivered robust growth in Skin Care and Health & Wellbeing, partially offset by GST-led moderation in Hair Care.
- The segment reported 9% USG and flat volume growth, driven by strong performance in Skin Care and Health & Wellbeing.
- Hair Care continued to strengthen its market leadership during the quarter; however, turnover declined YoY due to the transitory impact of GST rate rationalization.

- Skin Care, including Colour Cosmetics, grew in high-single digits, supported by continued momentum in the Future Core and Market Makers portfolio, along with well-executed winter loading ahead of the season.
- Channels of the Future maintained its competitive double-digit growth trajectory.
- Health & Wellbeing sustained strong momentum, led by OZiva's triple-digit growth.
- During the quarter, the company launched Pond's Hydra Miracle Ultralight Biome moisturizer, offering advanced hydration and microbiome benefits; Vaseline Cloud Soft, specially formulated for Indian facial skin; and OZiva Phyto Ceramides + Collagen Builder, a science-backed ingestible skincare supplement that helps restore the skin barrier and boost collagen production.
- Minimalist delivered strong double-digit growth in 1HFY26.

#### Personal care

- Personal Care reported flat sale growth, while UVG declined in high single digit during the quarter, impacted by the GST rate transition.
- Skin Cleansing delivered a competitive performance, supported by double-digit growth in premium soaps.
- Bodywash continued to strengthen its competitive position in the category.
- Oral Care witnessed a marginal decline, though Closeup recorded low-single digit growth.
- Premiumization remained a key focus area, highlighted by the re-launch of Pears with refreshed packaging and proposition, and the expansion of the Lux International soap range.

#### Food & Refreshment (F&R)

- Foods delivered 3% USG with low-single digit UVG during the quarter.
- Beverages (Tea and Coffee) grew in double digits, supporting the overall segment performance.
- Tea recorded high-single digit growth, driven by a healthy mix of price and volume, while Coffee sustained its strong double-digit growth momentum.
- Early green shoots were visible in Lifestyle Nutrition, with sustained UVG; however, turnover declined due to pricing actions taken in previous quarters to refine the pack-price architecture.
- Packaged Foods delivered a subdued performance amid the GST transition. Market Makers continued its robust growth momentum during the quarter.
- Ice Cream turnover declined YoY, impacted by prolonged monsoons in parts of the country and the GST transition.
- The quarter also saw the launch of Horlicks PRO Fitness, a science-backed meal replacement solution, and BRU Gold Edition, offering a premium coffee experience for consumers.

**Exhibit 2: Career trajectory of HUVR's new CFO, Mr. Niranjan Gupta (effective 1<sup>st</sup> Nov'25)**

## Niranjan Gupta



Source: Company presentation, MOFSL


## Story in charts

### Exhibit 3: New age GST reforms




Source: Company presentation, MOFSL

### Exhibit 4: Underlying volume growth was flat in 2QFY26




Source: Company, MOFSL

### Exhibit 5: Gross margin contracted 20bp YoY to 51.4%




Source: Company, MOFSL

### Exhibit 6: A&P spending expanded 80bp YoY to 10.2%




Source: Company, MOFSL

**Exhibit 7: Employee expenses declined 60bp YoY to 4.6%**




Source: Company, MOFSL

**Exhibit 8: Other expenses rose 40bp YoY to 13.6%**



Source: Company, MOFSL

**Exhibit 9: EBITDA margin contracted 80bp YoY to 23%**



Source: MOFSL, Company

## Valuation and view


- We largely maintain our estimates for FY26-FY28.
- The company plans to focus aggressively on volume acceleration, alongside new launches and the reactivation of its value proposition, which is expected to drive further growth from 2HFY26 onwards.
- We expect supportive macroeconomic factors to act as a catalyst for boosting consumption sentiment. As a market leader in most staple categories, coupled with its strategic initiatives, HUVR is well-positioned to benefit the most.
- We model an 8%/8%/9% revenue, EBITDA, and APAT CAGR over FY25-28E. With various strategies underway, optimism is building for stronger operational performance in the coming quarters. We believe the new leadership is well-positioned to capitalize on its volume growth aspirations amid supportive macro drivers. We reiterate our BUY rating on the stock with a TP of INR3,050 (55x on Sep'27E EPS).

### Exhibit 10: We largely maintain our EPS estimates for FY26-FY28


(INR b)	New estimates			Old estimates			Change (%)		
	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E
Sales	672.8	729.8	788.2	673.6	731.8	790.4	-0.1%	-0.3%	-0.3%
EBITDA	154.4	172.8	185.8	154.4	173.1	186.1	0.0%	-0.2%	-0.2%
PAT	107.7	122.5	132.6	108.3	123.1	133.2	-0.6%	-0.4%	-0.4%

Source: MOFSL

### Exhibit 11: P/E (x) for HUVR



### Exhibit 12: P/E (x) for the Consumer sector



## Financials and valuations

Income Statement									(INR b)
Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
<b>Total Revenue</b>	<b>397.8</b>	<b>470.3</b>	<b>524.5</b>	<b>605.8</b>	<b>619.0</b>	<b>631.2</b>	<b>672.8</b>	<b>729.8</b>	<b>788.2</b>
Change (%)	1.2	18.2	11.5	15.5	2.2	2.0	6.6	8.5	8.0
COGS	182.6	221.5	257.4	317.2	297.6	305.8	329.7	355.4	383.9
<b>Gross Profit</b>	<b>215.2</b>	<b>248.8</b>	<b>267.1</b>	<b>288.6</b>	<b>321.4</b>	<b>325.4</b>	<b>343.1</b>	<b>374.4</b>	<b>404.3</b>
Gross Margin (%)	54.1	52.9	50.9	47.6	51.9	51.6	51.0	51.3	51.3
Operating Exp	116.6	132.5	138.5	147.2	174.7	176.9	188.7	201.6	218.6
<b>EBITDA</b>	<b>98.6</b>	<b>116.3</b>	<b>128.6</b>	<b>141.5</b>	<b>146.6</b>	<b>148.5</b>	<b>154.4</b>	<b>172.8</b>	<b>185.8</b>
Change (%)	11.0	17.9	10.6	10.0	3.6	1.3	3.9	11.9	7.5
Margin (%)	24.8	24.7	24.5	23.4	23.7	23.5	22.9	23.7	23.6
Depreciation	10.0	10.7	10.9	11.4	12.2	13.6	14.4	14.9	15.3
Int. and Fin. Charges	1.2	1.2	1.1	1.1	3.3	4.0	4.0	4.1	4.2
Other Income - Recurring	6.3	4.1	2.6	5.1	8.1	10.2	9.3	10.3	11.3
<b>Profit before Taxes</b>	<b>93.7</b>	<b>108.5</b>	<b>119.2</b>	<b>134.1</b>	<b>139.2</b>	<b>141.2</b>	<b>145.2</b>	<b>164.1</b>	<b>177.6</b>
Change (%)	4.9	15.7	9.9	12.5	3.8	1.4	2.9	13.0	8.2
Margin (%)	23.9	23.4	23.1	22.5	22.8	22.7	21.9	22.8	22.8
Tax	24.1	26.1	29.9	32.0	36.4	37.4	33.7	41.3	44.7
Deferred Tax	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax Rate (%)	25.7	24.0	25.1	23.9	26.2	26.5	23.2	25.2	25.2
<b>Profit after Taxes</b>	<b>67.4</b>	<b>81.2</b>	<b>88.5</b>	<b>102.0</b>	<b>102.7</b>	<b>104.2</b>	<b>107.7</b>	<b>122.5</b>	<b>132.6</b>
Change (%)	12.0	20.5	9.0	15.2	0.7	1.4	3.3	13.8	8.2
Margin (%)	17.2	17.5	17.2	17.1	16.8	16.7	16.2	17.0	17.1
<b>Reported PAT</b>	<b>67.7</b>	<b>80.0</b>	<b>88.9</b>	<b>101.2</b>	<b>102.8</b>	<b>106.5</b>	<b>111.3</b>	<b>122.5</b>	<b>132.6</b>

Balance Sheet									(INR b)
Y/E March	FY20	FY21	FY22E	FY23E	FY24E	FY25	FY26E	FY27E	FY28E
Share Capital	2.2	2.3	2.3	2.4	2.4	2.4	2.4	2.4	2.4
Reserves	80.1	474.4	488.3	500.7	509.8	491.7	500.6	517.4	537.3
<b>Net Worth</b>	<b>82.3</b>	<b>476.7</b>	<b>490.6</b>	<b>503.0</b>	<b>512.2</b>	<b>494.0</b>	<b>503.0</b>	<b>519.8</b>	<b>539.6</b>
Loans	0.2	0.2	0.3	3.2	2.2	2.1	2.3	2.6	2.8
<b>Capital Employed</b>	<b>82.5</b>	<b>476.9</b>	<b>490.9</b>	<b>506.2</b>	<b>514.4</b>	<b>496.1</b>	<b>505.3</b>	<b>522.3</b>	<b>542.4</b>
Gross Block	108.3	578.6	589.8	613.3	636.1	655.5	670.5	685.5	700.5
Less: Accum. Depn.	-53.5	-64.2	-75.1	-86.5	-98.6	-112.2	-126.6	-141.5	-156.8
<b>Net Fixed Assets incl Goodwill</b>	<b>54.8</b>	<b>514.4</b>	<b>514.7</b>	<b>526.8</b>	<b>537.4</b>	<b>543.4</b>	<b>543.9</b>	<b>544.1</b>	<b>543.7</b>
Capital WIP	6.0	7.5	13.1	11.3	10.3	10.1	5.0	2.5	1.3
Investment in Subsidiaries	0.0	0.0	0.0	0.7	0.7	0.6	0.0	0.0	0.0
Current Investments	12.5	27.1	35.2	28.1	45.6	37.5	42.5	47.5	52.5
Deferred Charges	2.8	-59.7	-61.3	-64.1	-65.5	-66.7	-66.7	-66.7	-66.7
<b>Curr. Assets, L&amp;A</b>	<b>125.4</b>	<b>138.5</b>	<b>142.0</b>	<b>163.9</b>	<b>191.0</b>	<b>207.1</b>	<b>190.5</b>	<b>223.9</b>	<b>260.6</b>
Inventory	27.7	35.8	41.0	42.5	40.2	44.2	46.8	50.7	54.7
Account Receivables	11.5	17.6	22.4	30.8	30.0	38.2	40.7	44.2	47.7
Cash and Bank Balance	51.1	44.7	38.5	46.8	75.6	75.5	27.3	47.1	69.4
Others	35.1	40.4	40.2	43.8	45.2	49.2	75.7	82.0	88.8
<b>Curr. Liab. and Prov.</b>	<b>119.1</b>	<b>150.8</b>	<b>152.9</b>	<b>160.5</b>	<b>205.1</b>	<b>235.9</b>	<b>210.0</b>	<b>229.0</b>	<b>249.0</b>
Account Payables	84.7	88.0	90.7	95.7	104.9	113.2	106.3	115.3	124.6
Other Liabilities	8.5	23.0	22.1	23.6	23.8	52.2	26.2	28.4	30.7
Provisions	25.9	39.7	40.1	41.2	76.4	70.5	77.5	85.3	93.8
<b>Net Current Assets</b>	<b>6.3</b>	<b>-12.3</b>	<b>-10.9</b>	<b>3.4</b>	<b>-14.1</b>	<b>-28.8</b>	<b>-19.5</b>	<b>-5.1</b>	<b>11.6</b>
<b>Application of Funds</b>	<b>82.5</b>	<b>476.9</b>	<b>490.9</b>	<b>506.2</b>	<b>514.4</b>	<b>496.1</b>	<b>505.3</b>	<b>522.3</b>	<b>542.4</b>

E: MOSL Estimates

## Financials and valuations

### Ratios

Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
<b>Basic (INR)</b>									
EPS	<b>31.2</b>	<b>34.6</b>	<b>37.7</b>	<b>43.4</b>	<b>43.7</b>	<b>44.3</b>	<b>45.8</b>	<b>52.1</b>	<b>56.4</b>
Cash EPS	36.2	38.5	41.8	48.2	48.9	50.1	52.0	58.5	63.0
BV/Share	38.0	203.0	208.9	214.1	217.9	210.2	214.0	221.2	229.6
DPS	25.0	31.0	34.0	39.0	42.0	53.0	42.0	45.0	48.0
Payout %	94.6	91.5	91.5	89.8	96.1	119.6	91.7	86.3	85.0
<b>Valuation (x)</b>									
P/E	83.5	75.2	69.0	59.9	59.5	58.7	56.8	49.9	46.1
Cash P/E	71.8	67.6	62.2	53.9	53.2	51.9	50.0	44.5	41.3
EV/Sales	14.2	13.1	11.8	10.2	9.9	9.7	9.2	8.4	7.8
EV/EBITDA	56.6	52.1	47.2	42.9	41.2	40.6	39.4	35.1	32.5
P/BV	68.4	12.8	12.4	12.1	11.9	12.4	12.1	11.8	11.3
Dividend Yield (%)	1.0	1.2	1.3	1.5	1.6	2.0	1.6	1.7	1.8
<b>Return Ratios (%)</b>									
RoE incl. Goodwill	83.8	29.1	18.3	20.5	20.2	20.7	21.6	24.0	25.0
RoCE incl. Goodwill	116.9	39.2	24.8	27.1	27.9	28.7	29.8	32.7	34.1
<b>Working Capital Ratios</b>									
Debtor (Days)	10.7	13.9	15.8	18.9	17.9	22.4	22.4	22.4	22.4
<b>Leverage Ratio</b>									
Debt/Equity (x)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

Cash Flow Statement <span style="float: right;">(INR b)</span>									
Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
OP/(loss) before Tax	91.7	106.1	118.7	133.5	139.3	144.2	145.2	164.1	177.6
Financial other income	-4.5	-0.7	-1.5	-4.1	-6.1	-8.4	8.3	4.1	4.2
Depreciation	10.0	11.3	11.1	11.5	12.2	13.6	14.4	14.9	15.3
Net Interest Paid	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Direct Taxes Paid	-25.1	-24.1	-27.8	-31.4	-3.8	-22.7	-33.7	-41.3	-44.7
(Incr)/Decr in WC	4.1	-1.0	-10.0	-9.6	13.1	-7.9	-62.6	-0.3	-0.6
<b>CF from Operations</b>	<b>76.2</b>	<b>91.6</b>	<b>90.5</b>	<b>99.9</b>	<b>154.7</b>	<b>118.9</b>	<b>71.6</b>	<b>141.4</b>	<b>151.8</b>
Other Items	-9.2	-21.9	2.1	15.5	32.0	-44.3	-2.8	5.7	6.3
(Incr)/Decr in FA	-8.1	-6.4	-10.8	-10.1	-14.6	-12.6	-10.0	-12.5	-13.7
<b>Free Cash Flow</b>	<b>68.1</b>	<b>85.2</b>	<b>79.7</b>	<b>89.8</b>	<b>140.1</b>	<b>106.2</b>	<b>61.7</b>	<b>129.0</b>	<b>138.0</b>
(Pur)/Sale of Investments	22.8	23.4	-7.9	-7.4	-43.0	69.0	-4.4	-5.0	-5.0
<b>CF from Invest.</b>	<b>5.5</b>	<b>-5.0</b>	<b>-16.6</b>	<b>-2.1</b>	<b>-25.5</b>	<b>12.1</b>	<b>-17.1</b>	<b>-11.8</b>	<b>-12.5</b>
Dividend Paid	-52.0	-88.1	-75.3	-84.7	-94.2	-124.7	-98.7	-105.8	-112.8
Others	-15.2	-5.0	-4.9	-5.6	-5.3	-6.3	-4.0	-4.1	-4.2
<b>CF from Fin. Activity</b>	<b>-68.2</b>	<b>-93.1</b>	<b>-80.2</b>	<b>-89.5</b>	<b>-100.3</b>	<b>-131.0</b>	<b>-102.7</b>	<b>-109.9</b>	<b>-117.0</b>
<b>Incr/Decr of Cash</b>	<b>13.6</b>	<b>-6.4</b>	<b>-6.3</b>	<b>8.3</b>	<b>28.8</b>	<b>-0.1</b>	<b>-48.2</b>	<b>19.8</b>	<b>22.3</b>
Add: Opening Balance	37.6	51.1	44.7	38.5	46.8	75.6	75.5	27.3	47.1
<b>Closing Balance</b>	<b>51.1</b>	<b>44.7</b>	<b>38.5</b>	<b>46.8</b>	<b>75.6</b>	<b>75.5</b>	<b>27.3</b>	<b>47.1</b>	<b>69.4</b>

E: MOSL Estimates

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

## NOTES

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

\*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

#### Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations). Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on [www.motilaloswal.com](http://www.motilaloswal.com). MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/Lis%20of%20Associate%20companies.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at [www.nseindia.com](http://www.nseindia.com), [www.bseindia.com](http://www.bseindia.com). Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

#### Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

#### For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

#### For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

#### For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to [grievances@motilaloswal.com](mailto:grievances@motilaloswal.com).

Nainesh Rajani

Email: [nainesh.rajani@motilaloswal.com](mailto:nainesh.rajani@motilaloswal.com)

Contact: (+65) 8328 0276

#### Specific Disclosures

1. Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies).  
MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.  
Nature of Financial interest is holding equity shares or derivatives of the subject company
2. Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.  
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No
3. Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.  
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
4. Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.  
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
5. Research Analyst has not served as an officer, director or employee of subject company(ies).
6. MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
7. MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.

8. MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
9. MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
10. MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

#### Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

#### Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no warranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

#### Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alterations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; [www.motilaloswal.com](http://www.motilaloswal.com). Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN : 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to [query@motilaloswal.com](mailto:query@motilaloswal.com). In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to [grievances@motilaloswal.com](mailto:grievances@motilaloswal.com), for DP to [dpgrivances@motilaloswal.com](mailto:dpgrivances@motilaloswal.com).